

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
21 March 2019 (21.03.2019)



(10) International Publication Number
WO 2019/054944 A1

(51) International Patent Classification:

C07D 401/12 (2006.01) A61K 31/4155 (2006.01)
C07D 401/04 (2006.01) A61K 31/4178 (2006.01)
C07D 401/14 (2006.01) A61K 31/426 (2006.01)
C07D 231/12 (2006.01) A61K 31/4427 (2006.01)
C07D 233/58 (2006.01) A61P 35/00 (2006.01)
C07D 277/22 (2006.01)

(21) International Application Number:

PCT/SG2018/050466

(22) International Filing Date:

12 September 2018 (12.09.2018)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

10201707444W 12 September 2017 (12.09.2017) SG

(71) Applicant: **AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH** [SG/SG]; 1 Fusionopolis Way, #20-10, Connexis North Tower, Singapore 138632 (SG).

(72) Inventors: **HO, Soo Yei**; c/o Experimental Therapeutics Centre, 11 Biopolis Way, Helios, #03-10/11, Singapore 138667 (SG). **POULSEN, Anders**; c/o Experimental Therapeutics Centre, 11 Biopolis Way, Helios, #03-10/11, Singapore 138667 (SG). **TAN, Sum Wai Eldwin**; c/o Experimental Therapeutics Centre, 11 Biopolis Way, Helios, #03-10/11, Singapore 138667 (SG). **ANG, Shi Hua**; c/o Experimental Therapeutics Centre, 11 Biopolis Way, Helios, #03-10/11, Singapore 138667 (SG). **KELLER, Thomas Hugo**; c/o Experimental Therapeutics Centre, 11 Biopolis Way, Helios, #03-10/11, Singapore 138667 (SG).

(74) Agent: **SPRUSON & FERGUSON (ASIA) PTE LTD**; P.O. Box 1531, Robinson Road Post Office, Singapore 903031 (SG).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME,

MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).


Declarations under Rule 4.17:

— of inventorship (Rule 4.17(iv))

Published:

— with international search report (Art. 21(3))

(54) Title: COMPOUNDS USEFUL AS INHIBITORS OF ISOPRENYLCYSTEINE CARBOXYL METHYLTRANSFERASE



(57) Abstract: The present invention relates to compounds of general Formula (I), and/or tautomers, enantiomers, solvates, hydrates, and pharmaceutically acceptable salts thereof. The present invention also relates to compounds of Formula (I) for use in therapy, methods of treating isoprenylcysteine carboxyl methyltransferase (ICMT) related disorders or uses of compounds of Formula (I) in the manufacture of a medicament for the treatment of ICMT-related disorders, wherein the disorder is cancer and/or progeria. The present invention further relates to processes for synthesizing compounds of Formula (I).

WO 2019/054944 A1